Switch to:
Also traded in: Germany, Mexico, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.01
SHPGF's Cash to Debt is ranked lower than
99% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. SHPGF: 0.01 )
Ranked among companies with meaningful Cash to Debt only.
SHPGF' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 1.34 Max: No Debt
Current: 0.01
Equity to Asset 0.43
SHPGF's Equity to Asset is ranked lower than
76% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. SHPGF: 0.43 )
Ranked among companies with meaningful Equity to Asset only.
SHPGF' s Equity to Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.59 Max: 0.85
Current: 0.43
0.25
0.85
Interest Coverage 19.41
SHPGF's Interest Coverage is ranked lower than
73% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SHPGF: 19.41 )
Ranked among companies with meaningful Interest Coverage only.
SHPGF' s Interest Coverage Range Over the Past 10 Years
Min: 2.96  Med: 24.85 Max: 55.13
Current: 19.41
2.96
55.13
F-Score: 5
Z-Score: 2.29
M-Score: -2.56
WACC vs ROIC
14.48%
11.23%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 22.65
SHPGF's Operating margin (%) is ranked higher than
87% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. SHPGF: 22.65 )
Ranked among companies with meaningful Operating margin (%) only.
SHPGF' s Operating margin (%) Range Over the Past 10 Years
Min: -56.61  Med: 21.37 Max: 35.13
Current: 22.65
-56.61
35.13
Net-margin (%) 19.87
SHPGF's Net-margin (%) is ranked higher than
88% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -74.36 vs. SHPGF: 19.87 )
Ranked among companies with meaningful Net-margin (%) only.
SHPGF' s Net-margin (%) Range Over the Past 10 Years
Min: -59.59  Med: 16.13 Max: 56.55
Current: 19.87
-59.59
56.55
ROE (%) 13.79
SHPGF's ROE (%) is ranked higher than
89% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. SHPGF: 13.79 )
Ranked among companies with meaningful ROE (%) only.
SHPGF' s ROE (%) Range Over the Past 10 Years
Min: -90.17  Med: 17.82 Max: 49.38
Current: 13.79
-90.17
49.38
ROA (%) 7.08
SHPGF's ROA (%) is ranked higher than
87% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. SHPGF: 7.08 )
Ranked among companies with meaningful ROA (%) only.
SHPGF' s ROA (%) Range Over the Past 10 Years
Min: -37.5  Med: 9.76 Max: 31.55
Current: 7.08
-37.5
31.55
ROC (Joel Greenblatt) (%) 142.82
SHPGF's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. SHPGF: 142.82 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SHPGF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -396.76  Med: 109.10 Max: 345.44
Current: 142.82
-396.76
345.44
Revenue Growth (3Y)(%) 14.00
SHPGF's Revenue Growth (3Y)(%) is ranked higher than
69% of the 491 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. SHPGF: 14.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SHPGF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 13.00 Max: 28.5
Current: 14
0
28.5
EBITDA Growth (3Y)(%) 21.00
SHPGF's EBITDA Growth (3Y)(%) is ranked higher than
76% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. SHPGF: 21.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SHPGF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.3  Med: 24.80 Max: 42.4
Current: 21
-2.3
42.4
EPS Growth (3Y)(%) 24.70
SHPGF's EPS Growth (3Y)(%) is ranked higher than
80% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. SHPGF: 24.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SHPGF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.5  Med: 27.15 Max: 81.1
Current: 24.7
-8.5
81.1
» SHPGF's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-23)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with SHPGF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:XSWX:RO, OCSE:NOVO B, NAS:AMGN, NAS:GILD, NAS:CELG, NAS:BIIB » details
Traded in other countries:S7E.Germany, SHPG N.Mexico, SHP.UK, SHPG.USA,
Shire PLC is a specialty biopharmaceutical company that focuses on developing and marketing specialty medicines that address unmet patient needs.

Shire PLC was registered in Jersey on 28th January, 2008. It is a specialty biopharmaceutical company that focuses on developing and marketing specialty medicines that address unmet patient needs. The Company unified its business during 2013 by integrating the operations of the Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT) and Regenerative Medicine (RM) business units into a simplified One Shire organization. The Company has four commercial units that focus exclusively on the commercial execution of its In-Line products in the following specialist therapeutic areas: Rare Diseases, Neuroscience, Gastrointestinal (GI) and Internal Medicine. The clinical development, manufacturing and marketing of the Company's products is subject to governmental regulation in the US, the EU and other territories.

Ratios

vs
industry
vs
history
P/E(ttm) 29.20
SHPGF's P/E(ttm) is ranked higher than
51% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 29.15 vs. SHPGF: 29.20 )
Ranked among companies with meaningful P/E(ttm) only.
SHPGF' s P/E(ttm) Range Over the Past 10 Years
Min: 12.37  Med: 25.48 Max: 74.35
Current: 29.2
12.37
74.35
Forward P/E 11.01
SHPGF's Forward P/E is ranked higher than
79% of the 94 Companies
in the Global Biotechnology industry.

( Industry Median: 17.15 vs. SHPGF: 11.01 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 28.61
SHPGF's PE(NRI) is ranked higher than
53% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 30.43 vs. SHPGF: 28.61 )
Ranked among companies with meaningful PE(NRI) only.
SHPGF' s PE(NRI) Range Over the Past 10 Years
Min: 12.85  Med: 23.43 Max: 106.93
Current: 28.61
12.85
106.93
Price/Owner Earnings (ttm) 25.95
SHPGF's Price/Owner Earnings (ttm) is ranked higher than
60% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 37.01 vs. SHPGF: 25.95 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
SHPGF' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 11.1  Med: 21.14 Max: 60.14
Current: 25.95
11.1
60.14
P/B 3.59
SHPGF's P/B is ranked lower than
53% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. SHPGF: 3.59 )
Ranked among companies with meaningful P/B only.
SHPGF' s P/B Range Over the Past 10 Years
Min: 2.25  Med: 5.48 Max: 14.15
Current: 3.59
2.25
14.15
P/S 5.79
SHPGF's P/S is ranked higher than
70% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 12.41 vs. SHPGF: 5.79 )
Ranked among companies with meaningful P/S only.
SHPGF' s P/S Range Over the Past 10 Years
Min: 2.25  Med: 4.53 Max: 9.23
Current: 5.79
2.25
9.23
POCF 17.82
SHPGF's POCF is ranked higher than
62% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. SHPGF: 17.82 )
Ranked among companies with meaningful POCF only.
SHPGF' s POCF Range Over the Past 10 Years
Min: 7.66  Med: 16.64 Max: 26.94
Current: 17.82
7.66
26.94
EV-to-EBIT 30.42
SHPGF's EV-to-EBIT is ranked lower than
60% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 24.27 vs. SHPGF: 30.42 )
Ranked among companies with meaningful EV-to-EBIT only.
SHPGF' s EV-to-EBIT Range Over the Past 10 Years
Min: -16.1  Med: 16.40 Max: 42.6
Current: 30.42
-16.1
42.6
EV-to-EBITDA 20.88
SHPGF's EV-to-EBITDA is ranked higher than
52% of the 304 Companies
in the Global Biotechnology industry.

( Industry Median: 21.30 vs. SHPGF: 20.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
SHPGF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -21.3  Med: 13.10 Max: 28.6
Current: 20.88
-21.3
28.6
PEG 1.30
SHPGF's PEG is ranked higher than
73% of the 93 Companies
in the Global Biotechnology industry.

( Industry Median: 2.28 vs. SHPGF: 1.30 )
Ranked among companies with meaningful PEG only.
SHPGF' s PEG Range Over the Past 10 Years
Min: 0.47  Med: 1.07 Max: 2.14
Current: 1.3
0.47
2.14
Shiller P/E 50.54
SHPGF's Shiller P/E is ranked higher than
55% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 51.13 vs. SHPGF: 50.54 )
Ranked among companies with meaningful Shiller P/E only.
SHPGF' s Shiller P/E Range Over the Past 10 Years
Min: 42.92  Med: 108.85 Max: 469
Current: 50.54
42.92
469
Current Ratio 0.55
SHPGF's Current Ratio is ranked lower than
93% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. SHPGF: 0.55 )
Ranked among companies with meaningful Current Ratio only.
SHPGF' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.76 Max: 7.43
Current: 0.55
0.52
7.43
Quick Ratio 0.40
SHPGF's Quick Ratio is ranked lower than
93% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. SHPGF: 0.40 )
Ranked among companies with meaningful Quick Ratio only.
SHPGF' s Quick Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.51 Max: 7.07
Current: 0.4
0.4
7.07
Days Inventory 232.32
SHPGF's Days Inventory is ranked lower than
78% of the 446 Companies
in the Global Biotechnology industry.

( Industry Median: 127.50 vs. SHPGF: 232.32 )
Ranked among companies with meaningful Days Inventory only.
SHPGF' s Days Inventory Range Over the Past 10 Years
Min: 126.5  Med: 184.44 Max: 244.29
Current: 232.32
126.5
244.29
Days Sales Outstanding 76.01
SHPGF's Days Sales Outstanding is ranked lower than
59% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 63.27 vs. SHPGF: 76.01 )
Ranked among companies with meaningful Days Sales Outstanding only.
SHPGF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.71  Med: 67.24 Max: 72.82
Current: 76.01
47.71
72.82
Days Payable 124.33
SHPGF's Days Payable is ranked higher than
74% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 58.35 vs. SHPGF: 124.33 )
Ranked among companies with meaningful Days Payable only.
SHPGF' s Days Payable Range Over the Past 10 Years
Min: 80.31  Med: 110.24 Max: 161.12
Current: 124.33
80.31
161.12

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.42
SHPGF's Dividend Yield is ranked lower than
85% of the 206 Companies
in the Global Biotechnology industry.

( Industry Median: 1.23 vs. SHPGF: 0.42 )
Ranked among companies with meaningful Dividend Yield only.
SHPGF' s Dividend Yield Range Over the Past 10 Years
Min: 0.23  Med: 0.42 Max: 0.7
Current: 0.42
0.23
0.7
Dividend Payout 0.12
SHPGF's Dividend Payout is ranked higher than
91% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 0.31 vs. SHPGF: 0.12 )
Ranked among companies with meaningful Dividend Payout only.
SHPGF' s Dividend Payout Range Over the Past 10 Years
Min: 0.04  Med: 0.26 Max: 1.27
Current: 0.12
0.04
1.27
Dividend Growth (3y) 16.70
SHPGF's Dividend Growth (3y) is ranked higher than
74% of the 90 Companies
in the Global Biotechnology industry.

( Industry Median: 6.30 vs. SHPGF: 16.70 )
Ranked among companies with meaningful Dividend Growth (3y) only.
SHPGF' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 15.50 Max: 57.9
Current: 16.7
0
57.9
Forward Dividend Yield 0.42
SHPGF's Forward Dividend Yield is ranked lower than
73% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 1.34 vs. SHPGF: 0.42 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.91
SHPGF's Yield on cost (5-Year) is ranked lower than
67% of the 241 Companies
in the Global Biotechnology industry.

( Industry Median: 1.53 vs. SHPGF: 0.91 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SHPGF' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.5  Med: 0.91 Max: 1.52
Current: 0.91
0.5
1.52
3-Year Average Share Buyback Ratio -2.20
SHPGF's 3-Year Average Share Buyback Ratio is ranked higher than
81% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. SHPGF: -2.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SHPGF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -50.3  Med: -2.10 Max: 0.4
Current: -2.2
-50.3
0.4

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.17
SHPGF's Price/Projected FCF is ranked higher than
69% of the 180 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. SHPGF: 2.17 )
Ranked among companies with meaningful Price/Projected FCF only.
SHPGF' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.15  Med: 1.81 Max: 3.04
Current: 2.17
1.15
3.04
Price/Median PS Value 1.28
SHPGF's Price/Median PS Value is ranked lower than
70% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. SHPGF: 1.28 )
Ranked among companies with meaningful Price/Median PS Value only.
SHPGF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.54  Med: 0.96 Max: 2.78
Current: 1.28
0.54
2.78
Price/Peter Lynch Fair Value 1.16
SHPGF's Price/Peter Lynch Fair Value is ranked higher than
68% of the 60 Companies
in the Global Biotechnology industry.

( Industry Median: 1.68 vs. SHPGF: 1.16 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
SHPGF' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.54  Med: 1.27 Max: 2.92
Current: 1.16
0.54
2.92
Earnings Yield (Greenblatt) (%) 3.27
SHPGF's Earnings Yield (Greenblatt) (%) is ranked higher than
84% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. SHPGF: 3.27 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SHPGF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.3  Med: 5.60 Max: 9.2
Current: 3.27
2.3
9.2
Forward Rate of Return (Yacktman) (%) 26.31
SHPGF's Forward Rate of Return (Yacktman) (%) is ranked higher than
70% of the 115 Companies
in the Global Biotechnology industry.

( Industry Median: 14.18 vs. SHPGF: 26.31 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SHPGF' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.5  Med: 2.40 Max: 29.6
Current: 26.31
1.5
29.6

More Statistics

Revenue (TTM) (Mil) $6,638
EPS (TTM) $ 2.22
Beta1.69
Short Percentage of Float0.00%
52-Week Range $49.09 - 88.25
Shares Outstanding (Mil)592.14

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 8,861 11,470 8,781
EPS ($) 4.85 5.62 5.72
EPS without NRI ($) 4.85 5.62 5.72
EPS Growth Rate
(3Y to 5Y Estimate)
12.76%
» More Articles for SHPGF

Headlines

Articles On GuruFocus.com
Tweedy Browne Fund 4th Quarter Commentary Jan 27 2016 
John Paulson Sells Stake in Broadcom, Cuts Cablevision Holding Nov 18 2015 
Undervalued Baxalta Shares Target of Acquisition by Shire Plc Aug 05 2015 
Manning & Napier's Top 5 New Stock Buys of Q2 Jul 09 2015 
Manning & Napier Invests in Stake in Baidu Jul 08 2015 
Invesco European Growth Fund Parts With Two Stakes Jul 01 2015 
Andreas Halvorsen Increases Stake in Esperion Therapeutics Jun 29 2015 
Smart Guru John Paulson Bullish on Actavis Jun 18 2015 
8 Top Healthcare Stocks to Watch May 13 2015 
John Paulson's Stocks Trading at Low P/E May 04 2015 

More From Other Websites
Shire Expects to Wrap Up Baxalta Buy on June 3 May 27 2016
Why 58.com Inc (ADR) (WUBA)’s Stock Is Trending on Wednesday? May 25 2016
Why AstraZeneca plc and Shire plc are 2 growth stars May 24 2016
Specialty Pharma Stocks are Cheap…But Only Some are Worth Buying May 20 2016
Swedish-Born Tom Sandell Focuses on Equity Special Events Opportunities May 19 2016
You could beat the market with GlaxoSmithKline plc and Shire plc May 19 2016
As Shire-Baxalta merger nears, lots of unanswered questions remain May 12 2016
Could National Grid plc and Shire plc really make you rich? May 06 2016
Will Midatech Pharma plc be the next Shire plc? May 04 2016
Shire (SHPG) Tops Q1 Earnings, Baxalta Buyout Set for June May 02 2016
Why These Five Stocks Are on the Move Today? Apr 29 2016
FTSE 100 slides, but hangs on to monthly gain Apr 29 2016
[$$] Shire Posts First-Quarter Profit, Revenue Growth Apr 29 2016
Shire Quarterly Profit Tops Estimates as Drug Sales Soar Apr 29 2016
Royal London, Hermes take aim at UK plc pay plans Apr 28 2016
The Zacks Analyst Blog Highlights: Newell Brands, Hormel Foods, Shire and PAREXEL International Apr 28 2016
Shire director pay resolution just scrapes though at general meet Apr 28 2016
Shire director pay resolution just scrapes though at general meet Apr 28 2016
How Does Shire Lead the Angioedema Space? Apr 26 2016
What’s Happening with a Generic Version of Vyvanse? Apr 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)